Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

81.50
-1.4400-1.74%
Post-market: 81.500.00000.00%19:30 EDT
Volume:1.74M
Turnover:143.16M
Market Cap:15.96B
PE:-22.84
High:83.37
Open:82.89
Low:81.36
Close:82.94
52wk High:93.42
52wk Low:46.81
Shares:195.81M
Float Shares:154.00M
Volume Ratio:0.63
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-6.34
PE(LYR):-21.53

Loading ...

BridgeBio Oncology Therapeutics’ Principal Accounting Officer Marc Cobo files Form 3 ownership statement

Reuters
·
May 01

BridgeBio Oncology Therapeutics COO Idan Elmelech files initial beneficial ownership statement

Reuters
·
May 01

BridgeBio to report first-quarter results, host conference call after market close

Reuters
·
Apr 30

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Apr 30

BridgeBio price target raised to $102 from $95 at Truist

TIPRANKS
·
Apr 29

BridgeBio Pharma Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 29

Truist Financial Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

TIPRANKS
·
Apr 29

BridgeBio Pharma Inc : Leerink Partners Raises Target Price to $100 From $96

THOMSON REUTERS
·
Apr 29

U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings

Reuters
·
Apr 29

BofA ups BridgeBio price target, cites exclusivity ‘disappointment’ for pullback

TIPRANKS
·
Apr 29

BUZZ-BridgeBio slips as Pfizer patent deal disappoints investors

Reuters
·
Apr 29

BridgeBio turns negative after Pfizer details tamidis settlement

TIPRANKS
·
Apr 28

BridgeBio jumps 12% to $83.18 as Pfizer confirms tafamidis settlement

TIPRANKS
·
Apr 28

Analysts Offer Insights on Healthcare Companies: Cigna (CI) and BridgeBio Pharma (BBIO)

TIPRANKS
·
Apr 28

Apparent Hikma settlement ‘key positive’ for BridgeBio, says Barclays

TIPRANKS
·
Apr 28

BridgeBio Pharma Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 27

A Look At BridgeBio Pharma (BBIO) Valuation After Mixed Short Term Returns And Strong Long Term Gains

Simply Wall St.
·
Apr 26

BridgeBio Pharma announces annual shareholder meeting

Reuters
·
Apr 25

BridgeBio Pharma (BBIO) Receives a Buy from Piper Sandler

TIPRANKS
·
Apr 23

BridgeBio Oncology expects updated Phase 1 data for KRAS inhibitor BBO-11818 in H2 2026

Reuters
·
Apr 23